Advancements in Polymyalgia Rheumatica Treatment

Created using ChatSlide

This document provides valuable insights into a study on Polymyalgia Rheumatica, an inflammatory disease. It outlines current treatments, focusing on Secukinumab as a promising alternative. The study, conducted using a randomized, double-blind method, highlights patient group regimens and key outcomes, including remission rates and adverse events. High remission with Secukinumab presents potential new paths for treatment, supported by funding from Novartis and detailed clinical trial...